🔥Telegram İfşa

Today, our CMO will spotlight our innovation in #immunology at the virtual Stifel Immunology and Inflammation Forum. He’ll share progress across our industry-leading pipeline of oral degraders and highlight key upcoming milestones. Live webcast here: bit.ly/4mdhdD9

Our team is heading to Paris this week for the #EADVCongress! We’re excited to connect with fellow innovators in the #dermatology community and share presentations on our groundbreaking work to advance novel oral degrader medicines. Hope to see you there!

Looking forward to our presentations, AdBoard, and meeting many of you there! #EADV2025

We're hiring! If you're a clinical leader ready to shape strategy and drive innovation in dermatology and pulmonology, we want to hear from you. Apply now and help us redefine what's possible in immuno-inflammatory care: bit.ly/4mtbAkn #Hiring #ApplyNow #Careers

We’re thrilled to be featured in a late-breaking oral presentation at the ERS Congress next week. Our VP of Clinical Development will present on KT-621, our investigational, first-in-class, oral STAT6 degrader and the first STAT6-targeted medicine in clinical development

This #EczemaAwarenessMonth, we join National Eczema to #UnhideEczema and elevate the voices of those living with this chronic condition. We’re committed to deepening understanding of the burden eczema places on patients — from physical symptoms to emotional and social impacts.

Unfortunately I had to miss my favorite trip of the year!

Enjoyed the thoughtful conversation with BioCentury on the science and strategy behind targeted protein degradation. I’m proud of the work the Kymera Therapeutics team is doing advancing oral degrader with biologics-like profiles to transform treatment paradigms for all patients!

Today we shared new preclinical data for KT-579, our first-in-class, oral IRF5 degrader, in two posters at the American College of Rheumatology Convergence Annual Meeting. IRF5 is a high value, historically undrugged target that unlocks key biological pathways implicated in disease pathology. The data

Exciting new data that continues to demonstrate the unique profile of our IRF5 degrader program!

$KYMR Join us on November 4th for our quarterly financial results and latest company updates: bit.ly/47r8qrP

Today our Head of Research will be presenting at the Hanson Wade TPD & Induced Proximity Summit on our industry-leading oral immunology portfolio. She'll highlight KT-579, our first-in-class, oral IRF5 degrader with the potential to address multiple immuno-inflammatory diseases.

Hear from Ryan Camire, Scientist, Immunology, on how our unique approach and innovative research engine are enabling us to address historically undrugged targets in validated signaling pathways – like IRF5, a master regulator of immunity. #ICYMI: Explore our latest #ACR25

We were honored to host the Women in TPD & Induced Proximity annual networking event yesterday! This gathering brought together an incredible community committed to strengthening, recognizing, and supporting leadership and contributions in the field. #WomenInTPD #WomenInSTEM

Busy November!

Phenomenal quarter: KT-621 (STAT6 degrader): - completed dosing in our Ph1b AD (BROADEN) trial, data in December - Initiated our Ph2b AD (BROADEN2) trial, data by mid-2027 - on track to initiate our Ph2b Asthma (BREADTH) trial in Q1 2026 KT-579 (IRF5 degrader): close to FIH

Today at the Guggenheim Partners Healthcare Innovation Conference, our CEO, Nello Mainolfi, will highlight progress across our industry-leading oral immunology pipeline and discuss key upcoming milestones. Join the live webcast here: bit.ly/4hM4Ayl

#ICYMI: Earlier today, our CMO, Jared Gollob, spotlighted our groundbreaking work in targeted protein degradation and our vision for transforming #immunology at the UBS Global Healthcare Conference. Listen to the full webcast here: bit.ly/4oDR7es

Today at the Stifel Healthcare Conference, our CEO Nello Mainolfi will share how Kymera is driving innovation in #immunology through our industry-leading pipeline of oral degrader programs. Check out the live webcast here: bit.ly/4hX05Bd #RevolutionizingImmunology

Our community united for Veterans Day to honor those who serve by sending more than 100 thoughtful letters to veterans and active-duty service members through A Million Thanks. Special thanks to our team members Kris, Randy, and Brad for making this event possible – and to our